PDS Biotechnology Overview
- Year Founded
-
2005

- Status
-
Public
- Employees
-
31

- Stock Symbol
-
PDSB

- Investments
-
1
- Share Price
-
$1.56
- (As of Friday Closing)
PDS Biotechnology General Information
Description
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Contact Information
Website
www.pdsbiotech.comCorporate Office
- 303A College Road East
- Princeton, NJ 08540
- United States
Corporate Office
- 303A College Road East
- Princeton, NJ 08540
- United States
PDS Biotechnology Stock Performance
As of 14-Feb-2025, PDS Biotechnology’s stock price is $1.56. Its current market cap is $58.4M with 37.4M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.56 | $1.50 | $1.25 - $6.68 | $58.4M | 37.4M | 332K | -$1.17 |
PDS Biotechnology Financials Summary
As of 30-Sep-2024, PDS Biotechnology has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 107,296 | 123,959 | 328,034 | 161,125 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (39,347) | (43,028) | (41,672) | (21,434) |
Net Income | (40,556) | (42,942) | (40,855) | (16,918) |
Total Assets | 52,451 | 59,390 | 77,008 | 67,198 |
Total Debt | 24,669 | 23,852 | 23,473 | 490 |
PDS Biotechnology Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
PDS Biotechnology Comparisons
Industry
Financing
Details
PDS Biotechnology Competitors (71)
One of PDS Biotechnology’s 71 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
Aura Biosciences | Formerly VC-backed | Cambridge, MA | ||||
Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
Rakuten Medical | Venture Capital-Backed | San Diego, CA | ||||
BriaCell Therapeutics | Corporation | West Vancouver, Canada |
PDS Biotechnology Patents
PDS Biotechnology Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240316178-A1 | Recombinant protein vaccines formulated with enantio-specific cationic lipid r-dotap and methods of use thereof | Pending | 21-Oct-2022 | ||
US-20240317828-A1 | T cell activating immunotherapeutic for treatment of mucin 1 protein expressing human cancers | Pending | 19-Oct-2022 | ||
US-20240317833-A1 | Non-hla restricted t cell vaccine for tcr gamma alternate reading frame protein (tarp) protein expressing cancers | Pending | 17-Oct-2022 | ||
US-20220160867-A1 | Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection | Pending | 20-Nov-2020 | ||
CA-3198708-A1 | Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection | Pending | 20-Nov-2020 | A61K39/39 |
PDS Biotechnology Signals
PDS Biotechnology Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
PDS Biotechnology Acquisitions (1)
PDS Biotechnology’s most recent deal was a Merger/Acquisition with Edge Therapeutics for . The deal was made on 15-Mar-2019.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Edge Therapeutics | 15-Mar-2019 | Merger/Acquisition | Other Healthcare Technology Systems |
PDS Biotechnology ESG
Risk Overview
Risk Rating
Updated February, 15, 2024
35.44 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Pharmaceuticals
Subindustry
of 425
Rank
Percentile

PDS Biotechnology FAQs
-
When was PDS Biotechnology founded?
PDS Biotechnology was founded in 2005.
-
Where is PDS Biotechnology headquartered?
PDS Biotechnology is headquartered in Princeton, NJ.
-
What is the size of PDS Biotechnology?
PDS Biotechnology has 31 total employees.
-
What industry is PDS Biotechnology in?
PDS Biotechnology’s primary industry is Biotechnology.
-
Is PDS Biotechnology a private or public company?
PDS Biotechnology is a Public company.
-
What is PDS Biotechnology’s stock symbol?
The ticker symbol for PDS Biotechnology is PDSB.
-
What is the current stock price of PDS Biotechnology?
As of 14-Feb-2025 the stock price of PDS Biotechnology is $1.56.
-
What is the current market cap of PDS Biotechnology?
The current market capitalization of PDS Biotechnology is $58.4M.
-
Who are PDS Biotechnology’s competitors?
Arcus Biosciences, Aura Biosciences, Kite Pharma, Rakuten Medical, and BriaCell Therapeutics are some of the 71 competitors of PDS Biotechnology.
-
What is PDS Biotechnology’s annual earnings per share (EPS)?
PDS Biotechnology’s EPS for 12 months was -$1.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »